Correlating gene expression with chemical scaffolds of cytotoxic agents: ellipticines as substrates and inhibitors of MDR1

To facilitate a systematic study of chemoresistance across diverse classes of anticancer drug candidates, we performed correlation analyses between cytotoxic drug potency and gene expression in 60 tumor cell lines (NCI-60; NCI—National Cancer Institute). Ellipticine analogs displayed a range of correlation coefficients (r) with MDR1 (ABCB1, encoding multidrug resistance (MDR) protein MDR1 or P-glycoprotein). To determine MDR1 interactions of five ellipticines with diverse MDR1-r values, we employed MDR1-transport and cytotoxicity assays, using MDR1 inhibitors and siRNA-mediated MDR1 downregulation, in MDR1-overexpressing cells. Ellipticines with negative correlations—indicative of MDR1-mediated resistance—were shown to be MDR1 substrates, whereas those with neutral or positive correlations served as MDR1 inhibitors, which escape MDR1-mediated chemoresistance. Correlation with additional genes in the NCI-60 confirmed topoisomerases as ellipticine targets, but suggested distinct mechanisms of action and chemoresistance among them, providing a guide for selecting optimal drug candidates.

[1]  M. Fligner,et al.  Systematic analysis of large screening sets in drug discovery. , 2004, Current drug discovery technologies.

[2]  E. Wang,et al.  In vitro flow cytometry method to quantitatively assess inhibitors of P-glycoprotein. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[3]  N. Garbett,et al.  Extending nature's leads: the anticancer agent ellipticine. , 2004, Current medicinal chemistry. Anti-cancer agents.

[4]  R. Zittoun,et al.  Daunorubicin uptake by leukemic cells: correlations with treatment outcome and mdr1 expression. , 1993, Leukemia.

[5]  D. Scudiero,et al.  Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. , 1991, Journal of the National Cancer Institute.

[6]  Richard A. Johnson,et al.  Applied Multivariate Statistical Analysis , 1983 .

[7]  I. Pastan,et al.  Function and regulation of the human multidrug resistance gene. , 1993, Advances in cancer research.

[8]  M. Grever,et al.  Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. , 1994, Molecular pharmacology.

[9]  Brian Everitt,et al.  Cluster analysis , 1974 .

[10]  W. Sadee,et al.  Drug sensitivity and resistance genes in cancer chemotherapy: a chemogenomics approach. , 2003, Drug discovery today.

[11]  G. Gribble.  Chapter 7 Synthesis and Antitumor Activity of Ellipticine Alkaloids and Related Compounds , 1990 .

[12]  L V Rubinstein,et al.  Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening. , 1992, Cancer research.

[13]  William C Reinhold,et al.  Membrane Transporters and Channels , 2004, Cancer Research.

[14]  D. Botstein,et al.  A gene expression database for the molecular pharmacology of cancer , 2000, Nature Genetics.

[15]  Glenn J. Myatt,et al.  LeadScope: Software for Exploring Large Sets of Screening Data , 2000, J. Chem. Inf. Comput. Sci..

[16]  J N Weinstein,et al.  Mining the National Cancer Institute Anticancer Drug Discovery Database: cluster analysis of ellipticine analogs with p53-inverse and central nervous system-selective patterns of activity. , 1998, Molecular pharmacology.

[17]  G. S. Johnson,et al.  An Information-Intensive Approach to the Molecular Pharmacology of Cancer , 1997, Science.

[18]  P. Sonneveld,et al.  Modulation of multidrug-resistant multiple myeloma by cyclosporin , 1992, The Lancet.

[19]  I. Pastan,et al.  Biochemistry of multidrug resistance mediated by the multidrug transporter. , 1993, Annual review of biochemistry.

[20]  D. Scudiero,et al.  New colorimetric cytotoxicity assay for anticancer-drug screening. , 1990, Journal of the National Cancer Institute.

[21]  John N Weinstein,et al.  Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. , 2004, Cancer cell.

[22]  E. Wang,et al.  The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein. , 2001, Cancer research.

[23]  M. Grever,et al.  Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen. , 1995, The Journal of clinical investigation.

[24]  T. Tsuruo,et al.  Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. , 1989, Cancer research.

[25]  K. Paull,et al.  P-glycoprotein substrates and antagonists cluster into two distinct groups. , 1997, Molecular pharmacology.

[26]  K W Kohn,et al.  Intercalative binding of ellipticine to DNA. , 1975, Cancer research.

[27]  J. Weinstein,et al.  Pharmacogenomic analysis: correlating molecular substructure classes with microarray gene expression data , 2002, The Pharmacogenomics Journal.

[28]  D A Scudiero,et al.  The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets. , 1997, Anti-cancer drug design.

[29]  P. Roepe.  What is the precise role of human MDR 1 protein in chemotherapeutic drug resistance? , 2000, Current pharmaceutical design.

[30]  V. Ling,et al.  Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. , 1997, European journal of biochemistry.

[31]  J. Au,et al.  Mdr1 Transfection Causes Enhanced Apoptosis by Paclitaxel: An Effect Independent of Drug Efflux Function of P-Glycoprotein , 2001, Pharmaceutical Research.